Know Cancer

or
forgot password

Evaluation of HIV-Specific Immunological and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals


N/A
18 Years
60 Years
Open (Enrolling)
Both
HIV Infections

Thank you

Trial Information

Evaluation of HIV-Specific Immunological and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals


Rare individuals appear naturally resistant to overt HIV-1 infection despite repeated sexual
exposures. These individuals, referred to as exposed seronegatives (ES), represent a unique
population in which to evaluate mechanisms by which HIV-1 replication is either controlled
or aborted. The purpose of the study is to analyze HIV-specific immune responses, both
cellular and humoral, that exist in seronegative individuals who have experienced multiple
exposures to HIV by sexual contact.

This study will follow participants for 2 years. Participants will have 25 study visits
during the study. Assessments will include HIV tests, viral load measurements, CD4 counts,
pregnancy tests, and physical exams.


Inclusion Criteria:



- Good general health

- HIV uninfected

- Repeated exposures to HIV through unprotected sexual intercourse within the 2 years
prior to study entry

- Live in the greater Seattle area

- Plan to stay in the greater Seattle area for the 2 years after study entry

Exclusion Criteria:

- Pregnancy

Type of Study:

Observational

Study Design:

Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective

Principal Investigator

Julie McElrath, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Washington

Authority:

United States: Federal Government

Study ID:

5R01AI47086-03

NCT ID:

NCT00069485

Start Date:

December 1995

Completion Date:

Related Keywords:

  • HIV Infections
  • HIV Seronegativity
  • HIV Infections
  • Acquired Immunodeficiency Syndrome

Name

Location

Fred Hutchinson Cancer Research Center / University of Washington HIV Vaccine Trials UnitSeattle, Washington  98104